Kiniksa Pharmaceuticals (NASDAQ:KNSA) Releases Earnings Results, Beats Expectations By $0.03 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) posted its quarterly earnings data on Tuesday. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03, Briefing.com reports. Kiniksa Pharmaceuticals had a negative return on equity of 7.83% and a negative net margin of 3.10%. The firm had revenue of $108.30 million during the quarter, compared to analyst estimates of $90.60 million. During the same period in the prior year, the business posted ($0.02) EPS. Kiniksa Pharmaceuticals’s revenue was up 51.5% on a year-over-year basis.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA opened at $25.20 on Thursday. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of 229.11 and a beta of 0.38. The firm has a fifty day moving average price of $19.72 and a 200 day moving average price of $19.37. Kiniksa Pharmaceuticals has a fifty-two week low of $14.12 and a fifty-two week high of $27.88.

Analysts Set New Price Targets

KNSA has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price objective on Kiniksa Pharmaceuticals from $26.00 to $30.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Wells Fargo & Company began coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, May 3rd. They issued an “overweight” rating and a $34.00 price target for the company. Evercore ISI raised their price objective on shares of Kiniksa Pharmaceuticals from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Finally, Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday. Four analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $32.00.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.